GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XTER:NOV) » Definitions » Deferred Tax

Novo Nordisk AS (XTER:NOV) Deferred Tax : €3,713 Mil (TTM As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Novo Nordisk AS Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Novo Nordisk AS's change in deferred tax for the three months ended in Mar. 2025 was €1,072 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2025 was €3,713 Mil.

Novo Nordisk AS Deferred Tax Historical Data

The historical data trend for Novo Nordisk AS's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Deferred Tax Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,477.49 1,522.70 1,819.61 2,816.29 3,513.55

Novo Nordisk AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 873.22 707.71 949.95 982.48 1,072.44

Novo Nordisk AS Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,713 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Deferred Tax Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XTER:NOV) » Definitions » Deferred Tax
Comparable Companies
OCSE:HLUN A OCSE:STENO LLY JNJ ABBV XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568 SHSE:600276 XTER:BAYN TSE:4578
Traded in Other Exchanges
NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
Website
https://www.novonordisk.com
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.